An analysis of our cohort of ~5000 patients with cardiomyopathies with the targeted gene panel identified three heterozygous TMPO/LAP2α variants (NM_003276.2) with MAF ≤ 0.0027% and classified them according to ACMG guidelines (see Section 2) as pathogenic or likely pathogenic. Here, TMPO is linked to cardiomyopathy.